Roivant Sciences Ltd (FRA:87S)
€ 10.975 -1.02 (-8.5%) Market Cap: 8.42 Bil Enterprise Value: 3.37 Bil PE Ratio: 2.16 PB Ratio: 1.74 GF Score: 60/100

Roivant Sciences Ltd to Review Results From the Chronic Period of TUSCANY-2 Investor Call Transcript

Jun 22, 2023 / 12:00PM GMT
Release Date Price: €8.3 (-3.49%)
Operator

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the Roivant Sciences' Investors Call. (Operator Instructions) Please be advised that today's conference may be recorded. I'll now hand the conference over to your speaker host, Stephanie Lee. Please go ahead.

Stephanie Lee Griffin
Roivant Sciences Ltd. - VP of Special Projects

Good morning, and thank you for joining today's call to review the chronic period data for RVT-3101 from the TUSCANY-2 Phase IIb study in ulcerative colitis. I'm Stephanie Lee from Roivant Sciences.

Presenting today, we have Matt Gline, CEO of Roivant; and Mayukh Sukhatme, President and Chief Investment Officer. For those dialing in via conference call, you can find the slides being presented today as well as the press release announcing these updates on our IR website at www.investor.roivant.com. We'll also be providing the current slide numbers as we present to help you follow along. I'd like to remind you that we'll be making

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot